Les risques cliniques liés a la BCG thérapie endovésicale. Diagnostic et traitement

Progres en Urologie

Volumn SUPPL., Issue , 1998, Pages 13-19

  Desgrandchamps, François ^a   Le Duc, Alain ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0007734667     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. ALLOUC H, BENOIT G, PARADIS V, BLANCHET P, JARDIN A. Le risque de complications au cours du traitement endovésical par le BCG pour tumeur superficielle de vessie. Presse Med. 1997, 26: 1284-8
2. BOHLE A, BALCK F, VON WIETERSHEIM J, JOCHAM D : The quality of life during intravesical bacillus Calmette-Guerin therapy. J Urol 1996, 155: 1221-1226
3. BOHLE A, SCHÜLLER J, KNIPPER A, HOFSTETTER : Bacillus Clamette-Guerin treatment and vesicorenal reflux Eur Urol 1990, 17: 125-128
4. BÖHLE A, THANHAUSER A, ULMER AJ, MATTERN T, ERNST M, FLAD HD, JOCHAM D : On the mode of action of intravesical bacillus Calmette-Guerin: in vitro characterization of BCG-activated killer cells Urol Res, 1994, 22 185-90
5. BOHLE A, VON WIETERSHEIM J, JOCHAM D . The balance between side-effects and sucess in intravesical therapy Aspect of quality of life in BCG-treated patients. In A Bohle and D Jocham Ed.: Optimal therapy for patients with high-risk superficial bladder cancer - controversy and consensus. Proceedings of the first Lübeck symposium on bladder cancer The Medicine Publishing Foundation, 1997: 37. 109-117
6. CHAZERAIN P, DESPLACES N, MAMOUDY P, LEONARD P, ZIZA JM : Prosthetic total knee infection with a bacillus Calmette-Guerin (BCG) strain after therapy for bladder cancer J Rheumatol 1993: 20: 2170-2171.
7. DE DIEGO A, ROGADO MC, PRIETO M, NAUFFAL D, PERPINA M : Disseminated pulmonary granulomas after intravesical bacillus Calmette-Guerin immunotherapy. Respiration 1997; 64: 304-306
8. DEHERTGH D, FIERER E, ORELL JA: Hypersensitivity reaction to bacillus Calmette-Guerin treated with plasmapheresis. Am J Med 1989; 86: 343-344
9. DE SAINT MARTIN L, BOIRON C, POVEDA JD, HERREMAN G : BCGite généralisée après instillations intravésicales de bacilles de Calmetle-Guérin. Press Med 1993; 22: 1352-1356
10. HAKIM S, HEANEY JA, HEINZ T, ZWOLAK RW : Psoas abscess following intravesiacl bacillus Calmette-Guerin for bladder cancer : a case report. J urol 1993; 150: 188-189
11. HELLINGER WC, OLDENBURG WA, ALVAREZ S : Vascular and other serious infections with mycobacterium after bacillus of Calmette-Guerin therapy for bladder cancer. Southern Med J 1995; 88: 1212-1216
12. IZES JK, BIHRLE W, THOMAS CB : Corticosteroid-associated fatal mycobacterial sepsis occuring 3 years after instillation of intravesical bacillus Calmette-Guerin. J urol, 1993; 150 1498-1500
13. KRISTANSSON M, GREEN P, MANNING HL, SLUTSKY AM, BRECHER SM, VON REYN CF, ARBEIT RD, MASLOW JN : Molecular confirmation of bacillus Calmette-Guerin as the cause of pulmonary infection following urinary tract instillation. Clin Infect Dis 1993; 17: 228-30
14. LAMM DL : Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am, 1992, 19: 565-572
15. LAMM DL, STEG A, BOCCON GIBOD L, MORALES A, HANNA MG, PAGANO F, ALFTHAN O, BROSMAN S, FISHER HAF, JAKSE G, CHISOLM GD, VAN DER MEIJDEN ADPM, DEBRUYNR FMJ : Complications of bacillus Calmette-Guerin immunotherapy : review of 2602 patients and comparaison of chemotherapy complications. EORTC Genitourinary Group Monograph 6: BCG in superficial bladder cancer, pages 335-355, 1989 Aln R Liss, Inc.
16. LAMM DL, STOGDILL VD, STOGDILL BJ, CRISPEN RG : Complications of bacillus Calmette-Guerin immunotherapy in 1278 patients with bladder cancer. J Urol, 1986, 135 : 272-27
17. LAMM DL, VAN DER MEIJDEN ADPM, MORALES A, BROSMAN SA, CATALONA WJ, HERR HW, SOLOWAY MS, STEG A, DEBRUYNE FMJ : Incidence and treatment of complications of bacillus Calmette-Guerin intiavesical therapy in superficial bladder cancer. J Urol, 1992, 147: 596-600
18. LARIVENS S, BOUVET E, VALLEE E : Infection à Mycobacterium Bovis souche BCG chez un adulte infécté par le VIH. Méd mal Infect. 1995;25:1222-3
19. LEEBEEK FWG, OUWENDIJK RJTH, KOLK AHJ, DEES A, MEEK JCHE, NIENHUIS JE, DINGEMANS-DUMAS AM : Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation. Gut 1996; 38: 616-618
20. MAHAIRAS GG, SABO PJ, MICKEY MJ, SINGH DC, STOVER CK : Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. Bovis. J Bacteriol, 1996; 178:1274-82
21. MCPARLAND C, COTTON DJ, GOWDA S, HOEPPNER VH, MARTIN WT, WECKWORTH PF : Miliary Mycobacterium bovis induced by intravesical bacille Calmette-Guerin immunotherapy Am Rev Respir Dis 1992; 146. 13330-1332
22. MOLINA JM, RABIAN C, D'AGAY MF, MODAI J: Hypersensnivity systemic reaction following intravesical bacillus Calmette-Guerin: successful treatment with steroids. J urol 1992; 147: 695-697
23. MORALES A : Long-term results and complications of intracavitary bacillus Clamette-Guerin therapy for bladder cancer. J Urol, 1984; 132: 457-459
24. MORALES A, EIDINGER D, BRUCE AW : Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol, 1976, 116: 180-183
25. MORGAN MB, ISEMAN MD Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical administration of bacillus Calmette-Guerin. Am J Med 1996; 100. 372-373
26. OATES RD, STILMANT MM, FREEDLUND MC, SIROKY MB : Granulomatous proitatitis following Calmette-Guerin immunotherapy of bladder cancer. J Urol, 1988; 140: 751-753
27. RIBERA M, BIELSA J, MANTEROLA JM, FERNANDEZ MT, FERRANDIZ C Mycobacterium bovis-BCG infection of the glans penis: a complication of intravesical administration of bacillus Calmette-Guerin Br J Dermatol 1995; 132: 309-319
28. ROZENBLIT A, WASSERMAN E, MARIN ML, VEITH FJ, CYNAMON J, ROZENBLIT G : Infected aortic aneurysm and vertebral osteomyelitis after bacillus Calmette-Guerin therapy. AJR 1996; 167: 711-713
29. SISKRON FT, VENABLE DD, GONZALES E, EASTHAM JA : Granulomatous mass in a nonrefluxing renal unit after Bacillus Calmette-Guerin therapy for bladder cancer. J Urol, 1997, 158: 882-883
30. SMITH MD, CHANDRAN G, PARKER A, YOUSSEF PP, AHERN M, COLEMAN M, MACARDLE P, ROBERTS-THOMSON P : Synovial membrane cytokine profiles in reactive arthritis secondary to intravesical bacillus Calmette-Guerin therapy. J Rheumatol 1997; 24: 752-758
31. STAMEY TA: pathogenesis and treatment of urinary tract infections. Baltimore, Williams & Wilkins company, 1980
32. STASSAR MJJG, VEGT PDJ, STEERENBERG PA, VAN DEN MEIJEN APM, MEIRING HD, DESSENS-KROON M, GEERTZEN HGM, DEN OTTER W: Effects of Isomazid (INH) on the BCG-induced local immune response after intravesical BCGtherapy for superficial bladder cancel Urol Res. 1994, 22: 177-184
33. STEG A, LELEU C, DEBRÉ B. BOCCON-GIBOD L, SICARD D : Systemic Bacillus Calmette-Guerin infection, «BCGitis» in patients treated by intravesical bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol 1989, 16: 161-164
34. STEG A, SICARD D, LELEU C, DEBRE B, BOCCON-GIBOD L : Systemic complications of intravesical BCG therapy for bladder cancer. Lancet, 1985, 899
35. STONE DR, ESTES III NAM, KLEMPNER MS Mycobacterium bovis infection of an implantable defibrillator following intravseical therapy with bacille Calmette-Guerin Clin Infect Dis 1993; 16: 825-826
36. TERRIS MK, MACY M, FREIHA FS : Transrectal ultrasound appearance of prostatic granulomas secondary to bacillus Calmette-Guerin instillation J Urol 1997; 158. 126-127
37. THALMANN GN, STUDER UE : Fever as positive prognostic factor of BCG therapy. In A Böhle and D Jocham Ed., Optimal therapy for patients with high-risk superficial bladder cancer - controversy and consensus. Proceedings of the first Lubeck symposium on bladder cancer. The Medicine Publishing Foundation, 1997; 37: 109-117
38. TUNCER S, TEKIN MI, OZEN H, BILEN C, UNAL S, REMZI D : Detection of bacillus Calmette-Guerin in the blood by polymerse chain reaction method of treated bladder cancer patients. J Urol 1997; 158: 2109-2112
39. VEGT PDJ, VAN DE MEIJDEN APM, SYLVESTER R, BRAUSI M, HÖLTL W, DE BALINCOURT C, and the member of the EORTC genitourinary group. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer protocol 30911. J Urol, 1997, 157: 1246-1249
40. WOLF TG, WOLF DG, HIGGINBOTTOM PA, DILLEY RB : Infection of a ruptured aortic aneurysm and an aortic graft with bacillus Calmette-Guerin after intravesical administration for bladder cancer J vasc Surg 1995; 22: 80-84
41. ZLOTTA AR, DROWART A, VAN VOOREN JP, DE COOK M, PIRSON M, PALFLIET K, JURION F, VANONCKELEN A, SIMON J, SCHULMAN CC, HUYGEN K : Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol, 1997; 157: 492-496